FDA Drug Recalls
1,739 recalls · Class I, newest first
Class I · High risk Terminated Nov 29, 2017
Reason Marketed Without An Approved NDA/ANDA: FDA analysis found this product to contain undeclared sildenafil, an FDA approved drug for the treatment of…
Class I · High risk Terminated Nov 19, 2017
Reason Marketed without an approved NDA/ANDA: Product contains undeclared active pharmaceutical ingredient (API) - Sildenafil.
Class I · High risk Terminated Nov 10, 2017
Reason Presence of Particulate Matter:Particulate identified as polyethylene, the primary constituent of the film and ports used to manufacture the bag in…
Class I · High risk Terminated Nov 9, 2017
Reason Non-sterility: confirmed microbial contamination with Achromobacter xylosoxidans
Class I · High risk Terminated Oct 27, 2017
Reason Labeling: Label MIX-UP. Blister Packages, Labeled as Midazolam injection, USP, 2 mg / 2 ml, Containing Syringes of Ondansetron Injection, USP, 4 mg…
Class I · High risk Terminated Oct 20, 2017
Reason SUPERPOTENT: Weight variations resulting in tablets that are sub and super potent
Class I · High risk Terminated Sep 20, 2017
Reason Marketed without an Approved NDA/ANDA; FDA analysis found product to be tainted with Sildenafil.
Class I · High risk Terminated Sep 15, 2017
Reason Marketed without an Approved NDA/ANDA: undeclared Active Pharmaceutical Ingredients sildenafil, desmethyl carbodenafil and tadalafil.
Class I · High risk Terminated Sep 15, 2017
Reason Marketed without an Approved NDA/ANDA: undeclared Active Pharmaceutical Ingredients sildenafil, desmethyl carbodenafil and tadalafil.
Class I · High risk Terminated Sep 15, 2017
Reason Marketed without an Approved NDA/ANDA: undeclared Active Pharmaceutical Ingredients sildenafil, desmethyl carbodenafil and tadalafil.
Class I · High risk Terminated Sep 15, 2017
Reason Marketed without an Approved NDA/ANDA: undeclared Active Pharmaceutical Ingredients sildenafil, desmethyl carbodenafil and tadalafil.
Class I · High risk Terminated Sep 15, 2017
Reason Temperature Abuse: A portion of this product lot was exposed to subfreezing temperatures, which is outside of the acceptable storage range listed on…
Class I · High risk Terminated Sep 5, 2017
Reason Non-Sterility:presence of cracked or chipped glass at the neck of Sterile Water for Injection vials.
Class I · High risk Terminated Aug 30, 2017
Reason Presence of Particulate Matter: glass particulate found in vial
Class I · High risk Terminated Aug 29, 2017
Reason Incorrect Product Formulation: product contains dexamethasone instead of hydrocortisone.
Class I · High risk Terminated Aug 7, 2017
Reason Labeling: Label mix-up, the product labeled as Pravastatin sodium tablets 40 mg was filled with Bupropion hydrochloride XL Tablets 300 mg.
Class I · High risk Terminated Aug 3, 2017
Reason Defective Delivery System: the dropper measurement markings may be reversed, shifted or missing.
Class I · High risk Terminated Aug 1, 2017
Reason Marketed Without An Approved NDA/ANDA: FDA analysis found the product to contain undeclared sildenafil and tadalafil and undeclared milk. The…
Class I · High risk Terminated Jul 24, 2017
Reason Marketed Without An Approved NDA/ANDA: Tainted Product Marketed As a Dietary Supplements: products found to be tainted with sibutramine making these…
Class I · High risk Terminated Jul 24, 2017
Reason Marketed Without An Approved NDA/ANDA: Tainted Product Marketed As a Dietary Supplements: products found to be tainted with sibutramine making these…
Class I · High risk Terminated Jul 21, 2017
Reason Marketed without an Approved NDA/ANDA;FDA analysis found product to be tainted with sildendafil and tadalafil
Class I · High risk Terminated Jul 17, 2017
Reason Marketed without an approved NDA/ANDA: presence of undeclared desmethyl carbodenafil and undeclared milk.
Class I · High risk Terminated Jul 5, 2017
Reason Marketed Without An Approved NDA/ANDA: Product contains Methylstenbolone or Dymethazine.
Class I · High risk Terminated Jul 5, 2017
Reason Marketed Without An Approved NDA/ANDA: Product contains Methylstenbolone or Dymethazine.
Class I · High risk Terminated Jun 22, 2017
Reason Marketed Without An Approved NDA/ANDA: FDA analysis found this product to contain undeclared sildenafil, an FDA approved drug for the treatment of…